Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Saifullah Nasir

Internal Medicine Schaumburg, IL Medical Doctor

NPI 1427343938 CMS profile 916181

1345 Wiley Rd Ste 111, Schaumburg, IL 60173

Open in the dashboard

General payments

$7,070

372 records reported · program years 2019–2025

Research payments

$216,733

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,475,456 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Saifullah Nasir of Schaumburg, IL is reported in the CMS Open Payments database as having received $7,070 across 372 general payments and $216,733 in research payments paid to them. Separately, studies naming them as principal investigator received $1,475,456 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $688 42
2024 General $1,028 68
2024 Research $216,733 2
2023 General $1,204 64
2022 General $1,271 57
2021 General $1,197 63
2020 General $985 49
2019 General $698 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Saifullah Nasir
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Saifullah Nasir were reported at $688. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Saifullah Nasir Internal Medicine median Middle half National median
2019 $698 $159 $48–$570 $163
2020 $985 $119 $33–$402 $114
2021 $1,197 $135 $37–$521 $132
2022 $1,271 $141 $42–$496 $149
2023 $1,204 $149 $45–$519 $160
2024 $1,028 $154 $47–$537 $164
2025 $688 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,815 99 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,239 47 payments
  3. Pfizer Inc. $958 67 payments
  4. AstraZeneca Pharmaceuticals LP $461 26 payments
  5. E.R. Squibb & Sons, L.L.C. $428 32 payments
  6. Janssen Pharmaceuticals, Inc $337 18 payments
  7. Amgen Inc. $257 10 payments
  8. Esperion Therapeutics, Inc. $253 12 payments
  9. AbbVie, Inc. $185 8 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $180 9 payments
  11. Other $957 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,039 370 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17 1 payment
  3. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. JARDIANCE $1,079 41 payments
  2. ENTRESTO Cardiovascular $930 51 payments
  3. ELIQUIS Cardiovascular;Metabolic Disease $880 63 payments
  4. ENTRESTO Cardiology/Vascular Diseases $674 35 payments
  5. PRADAXA $557 22 payments
  6. XARELTO $337 18 payments
  7. FARXIGA $312 18 payments
  8. NEXLETOL $253 12 payments
  9. LEQVIO $232 17 payments
  10. ELIQUIS Cardiovascular $226 12 payments
  11. Other $3,010 151 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $216,733 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 113 drugs

Part D claims

8,397

Median for Internal Medicine: 777

Drug cost

$1,070,921

Median for Internal Medicine: $73,373

Branded share of claims

17.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 311 $437,403
Xarelto Rivaroxaban Brand 104 $152,447
Jardiance Empagliflozin Brand 87 $135,143
Entresto Sacubitril/Valsartan Brand 63 $91,905
Ozempic Semaglutide Brand 33 $55,892
Farxiga Dapagliflozin Propanediol Brand 38 $51,387
Januvia Sitagliptin Phosphate Brand 13 $19,584
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $11,566
Metoprolol Succinate Generic 517 $8,685
Atorvastatin Calcium Generic 829 $8,435

The 10 drugs with the highest cost, of 113 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$251,308

Medicare's payments for the services billed

Medicare patients

1,040

Average age 77

Services billed

3,866

561 women, 479 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 43%
Heart failure 42%
Ischemic heart disease 42%
Atrial fibrillation 36%
Chronic kidney disease 33%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $232
$232 63 —
ELIQUIS
  • PFIZER INC. $169
  • E.R. Squibb & Sons, L.L.C. $15
$184 311 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $120
$120 38 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $75
$75 — —
NURTEC ODT
  • PFIZER INC. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

374 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record